HLA-DR activators are compounds or molecules that possess the ability to stimulate the expression or function of Human Leukocyte Antigen-DR (HLA-DR) molecules. HLA-DR is a specific class of major histocompatibility complex II (MHC II) molecules found on the surface of antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells. These molecules play a pivotal role in the immune system by presenting antigens, fragments of foreign substances like pathogens or proteins, to CD4+ T helper cells. The interaction between HLA-DR and CD4+ T cells is a crucial step in initiating the adaptive immune response, as it allows the immune system to recognize and mount a specific defense against invading pathogens.
Activation of HLA-DR involves a complex cascade of events. Typically, during an infection or immune response, antigen-presenting cells internalize and process antigens. These processed antigens are then loaded onto HLA-DR molecules within specialized compartments called endosomes. HLA-DR molecules, which consist of two chains (alpha and beta), each encoded by a distinct gene within the MHC II locus, then transport the antigenic fragments to the cell surface. Once displayed on the cell surface, the HLA-DR-antigen complex can interact with CD4+ T cells, leading to the activation of these T cells and the coordination of various immune responses. HLA-DR activators, therefore, influence and modulate the immune system's ability to recognize and respond to foreign invaders, making them essential components in the complex orchestration of immune defense mechanisms.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Pam3Cys-Ser-(Lys)4 trihydrochloride | 112208-04-5 | sc-202271 | 2 mg | $423.00 | ||
A synthetic triacylated lipopeptide that can activate Toll-like receptor 2 (TLR2), leading to an increase in HLA-DR expression. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $96.00 $166.00 $459.00 $1615.00 | 12 | |
LPS stimulates antigen-presenting cells via the TLR4 pathway, leading to upregulation of HLA-DR expression. | ||||||
GM-CSF | 83869-56-1 | sc-280759 | 5 µg | $516.00 | 1 | |
GM-CSF promotes the maturation of dendritic cells, leading to increased HLA-DR expression. | ||||||
Levamisole Hydrochloride | 16595-80-5 | sc-205730 sc-205730A | 5 g 10 g | $42.00 $67.00 | 18 | |
An immunomodulatory agent that can enhance HLA-DR expression on lymphocytes. | ||||||
Zymosan A from Saccharomyces cerevisiae | 58856-93-2 | sc-258367 sc-258367A | 250 mg 1 g | $88.00 $218.00 | 2 | |
A yeast-derived glucan that can activate immune cells through various pathways, including increasing HLA-DR expression. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates the PKC pathway, which can lead to enhanced HLA-DR expression. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $100.00 $300.00 $500.00 $1528.00 | 12 | |
A TLR7/8 agonist that can induce HLA-DR expression in dendritic cells. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $650.00 | 2 | |
A synthetic analog of double-stranded RNA that can activate TLR3, leading to upregulation of HLA-DR | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
An immunosuppressant that can influence HLA-DR expression on some cell types. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $70.00 $160.00 $290.00 | 2 | |
At high concentrations, Cholecalciferol can downregulate the expression of HLA-DR on dendritic cells. |